Combined comparative genomic hybridization and transcriptomic analyses of ovarian granulosa cell tumors point to novel candidate driver genes

被引:27
作者
Caburet, Sandrine [1 ,2 ,8 ,9 ]
Anttonen, Mikko [3 ,4 ,5 ]
Todeschini, Anne-Laure [1 ,2 ]
Unkila-Kallio, Leila [3 ,4 ]
Mestivier, Denis [1 ,2 ]
Butzow, Ralf [3 ,4 ,6 ,7 ]
Veitia, Reiner A. [1 ,2 ,8 ,9 ]
机构
[1] Inst Jacques Monod, F-75251 Paris, France
[2] Univ Paris Diderot Paris, Paris, France
[3] Univ Helsinki, Dept Obstet & Gynecol, Helsinki, Finland
[4] Univ Helsinki, Cent Hosp, Helsinki, Finland
[5] Univ Helsinki, Childrens Hosp, Helsinki, Finland
[6] Univ Helsinki, Dept Pathol, Helsinki, Finland
[7] Univ Helsinki, Cent Hosp, HUSLAB, Helsinki, Finland
[8] Univ Paris Diderot, Paris 13, France
[9] CNRS, Inst Jacques Monod, UMR 7592, Paris 13, France
来源
BMC CANCER | 2015年 / 15卷
基金
芬兰科学院;
关键词
Ovarian granulosa cell tumor; Driver genes; CGH; Transcriptomics; EPITHELIAL PROTEIN LOST; AAA-ATPASE NVL2; BREAST-CANCER; DOWN-REGULATION; FOXL2; MUTATION; DNA-DAMAGE; IN-VITRO; EXPRESSION; EPLIN; PROGRESSION;
D O I
10.1186/s12885-015-1283-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Ovarian granulosa cell tumors (GCTs) are the most frequent sex cord-stromal tumors. Several studies have shown that a somatic mutation leading to a C134W substitution in the transcription factor FOXL2 appears in more than 95% of adult-type GCTs. Its pervasive presence suggests that FOXL2 is the main cancer driver gene. However, other mutations and genomic changes might also contribute to tumor formation and/or progression. Methods: We have performed a combined comparative genomic hybridization and transcriptomic analyses of 10 adult-type GCTs to obtain a picture of the genomic landscape of this cancer type and to identify new candidate co-driver genes. Results: Our results, along with a review of previous molecular studies, show the existence of highly recurrent chromosomal imbalances (especially, trisomy 14 and monosomy 22) and preferential co-occurrences (i.e. trisomy 14/monosomy 22 and trisomy 7/monosomy 16q). In-depth analyses showed the presence of recurrently broken, amplified/duplicated or deleted genes. Many of these genes, such as AKT1, RUNX1 and LIMA1, are known to be involved in cancer and related processes. Further genomic explorations suggest that they are functionally related. Conclusions: Our combined analysis identifies potential candidate genes, whose alterations might contribute to adult-type GCT formation/progression together with the recurrent FOXL2 somatic mutation.
引用
收藏
页数:11
相关论文
共 64 条
  • [1] The genomic landscape of small intestine neuroendocrine tumors
    Banck, Michaela S.
    Kanwar, Rahul
    Kulkarni, Amit A.
    Boora, Ganesh K.
    Metge, Franziska
    Kipp, Benjamin R.
    Zhang, Lizhi
    Thorland, Erik C.
    Minn, Kay T.
    Tentu, Ramesh
    Eckloff, Bruce W.
    Wieben, Eric D.
    Wu, Yanhong
    Cunningham, Julie M.
    Nagorney, David M.
    Gilbert, Judith A.
    Ames, Matthew M.
    Beutler, Andreas S.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (06) : 2502 - 2508
  • [2] Mammostrat® as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy
    Bartlett, John M. S.
    Thomas, Jeremy
    Ross, Douglas T.
    Seitz, Robert S.
    Ring, Brian Z.
    Beck, Rodney A.
    Pedersen, Hans Christian
    Munro, Alison
    Kunkler, Ian H.
    Campbell, Fiona M.
    Jack, Wilma
    Kerr, Gillian R.
    Johnstone, Laura
    Cameron, David A.
    Chetty, Udi
    [J]. BREAST CANCER RESEARCH, 2010, 12 (04)
  • [3] Adult ovarian granulosa cell tumor transcriptomics: prevalence of FOXL2 target genes misregulation gives insights into the pathogenic mechanism of the p.Cys134Trp somatic mutation
    Benayoun, B. A.
    Anttonen, M.
    L'Hote, D.
    Bailly-Bechet, M.
    Andersson, N.
    Heikinheimo, M.
    Veitia, R. A.
    [J]. ONCOGENE, 2013, 32 (22) : 2739 - 2746
  • [4] Transcription factor FOXL2 protects granulosa cells from stress and delays cell cycle: role of its regulation by the SIRT1 deacetylase
    Benayoun, Berenice A.
    Georges, Adrien B.
    L'Hote, David
    Andersson, Noora
    Dipietromaria, Aurelie
    Todeschini, Anne-Laure
    Caburet, Sandrine
    Bazin, Claude
    Anttonen, Mikko
    Veitia, Reiner A.
    [J]. HUMAN MOLECULAR GENETICS, 2011, 20 (09) : 1673 - 1686
  • [5] Functional Exploration of the Adult Ovarian Granulosa Cell Tumor-Associated Somatic FOXL2 Mutation p.Cys134Trp (c.402C>G)
    Benayoun, Berenice A.
    Caburet, Sandrine
    Dipietromaria, Aurelie
    Georges, Adrien
    D'Haene, Barbara
    Pandaranayaka, P. J. Eswari
    L'Hote, David
    Todeschini, Anne-Laure
    Krishnaswamy, Sankaran
    Fellous, Marc
    De Baere, Elfride
    Veitia, Reiner A.
    [J]. PLOS ONE, 2010, 5 (01):
  • [6] Expression Status and Mutational Analysis of the PTEN and PI3K Subunit Genes in Ovarian Granulosa Cell Tumors
    Bittinger, Sophie
    Alexiadis, Maria
    Fuller, Peter J.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 (03) : 339 - 342
  • [7] Enrichr: interactive and collaborative HTML']HTML5 gene list enrichment analysis tool
    Chen, Edward Y.
    Tan, Christopher M.
    Kou, Yan
    Duan, Qiaonan
    Wang, Zichen
    Meirelles, Gabriela Vaz
    Clark, Neil R.
    Ma'ayan, Avi
    [J]. BMC BIOINFORMATICS, 2013, 14
  • [8] RUNX family: Regulation and diversification of roles through interacting proteins
    Chuang, Linda Shyue Huey
    Ito, Kosei
    Ito, Yoshiaki
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2013, 132 (06) : 1260 - 1271
  • [9] Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis
    Cohen, HY
    Lavu, S
    Bitterman, KJ
    Hekking, B
    Imahiyerobo, TA
    Miller, C
    Frye, R
    Ploegh, H
    Kessler, BM
    Sinclair, DA
    [J]. MOLECULAR CELL, 2004, 13 (05) : 627 - 638
  • [10] Biodistribution of radiolabeled adenosylcobalamin in patients diagnosed with various malignancies
    Collins, DA
    Hogenkamp, HPC
    O'Connor, MK
    Naylor, S
    Benson, LM
    Hardyman, TJ
    Thorson, LM
    [J]. MAYO CLINIC PROCEEDINGS, 2000, 75 (06) : 568 - 580